Chromocell Therapeutics Corporation (NYSE MKT:CHRO) — Market Cap & Net Worth
Market Cap & Net Worth: Chromocell Therapeutics Corporation (CHRO)
Chromocell Therapeutics Corporation (NYSE MKT:CHRO) has a market capitalization of $8.90 Million ($8.90 Million) as of October 12, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #27433 globally and #5697 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chromocell Therapeutics Corporation's stock price $22.46 by its total outstanding shares 6595850 (6.60 Million).
Chromocell Therapeutics Corporation Market Cap History: 2024 to 2025
Chromocell Therapeutics Corporation's market capitalization history from 2024 to 2025. Data shows growth from $4.35 Million to $148.14 Million (171.46% CAGR). Check Chromocell Therapeutics Corporation stock price for real-time trading data and today's change.
Chromocell Therapeutics Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chromocell Therapeutics Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CHRO cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CHRO by Market Capitalization
Companies near Chromocell Therapeutics Corporation in the global market cap rankings as of October 12, 2026. See CHRO equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to Chromocell Therapeutics Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Chromocell Therapeutics Corporation Historical Marketcap From 2024 to 2025
Between 2024 and today, Chromocell Therapeutics Corporation's market cap moved from $4.35 Million to $ 148.14 Million, with a yearly change of 171.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $148.14 Million | +3305.61% |
| 2024 | $4.35 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 1st, 2026 the market cap of Chromocell Therapeutics Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.90 Million USD |
| MoneyControl | $8.90 Million USD |
| MarketWatch | $8.90 Million USD |
| marketcap.company | $8.90 Million USD |
| Reuters | $8.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and id… Read more